Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 19, 2026, 4:17 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 169–192 of 603 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: EX Clear all
Recruiting No phase listed Observational Accepts healthy volunteers

In Vivo Real-time Detection of Circulating Melanoma Cells

NCT01776905
View directory record Official record
Conditions
Melanoma
Interventions
Not listed
Lead sponsor
University of Arkansas
Other
Eligibility
18 Years to 80 Years
Enrollment
75 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2027
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Jun 17, 2026 · Synced Oct 19, 2026, 4:17 PM EDT
Terminated Phase 2 Interventional Results available

Phase II Clinical Trial of Intraoral Grafting of Human Tissue Engineered Oral Mucosa

NCT01834326
View directory record Official record
Conditions
Disorder of Oral Mucous Membrane
Interventions
EVPOME (autogenous ex vivo produced oral mucosa equivalent), POM (Palatal oral mucosa)
Biological
Lead sponsor
Stephen E. Feinberg
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Sep 5, 2021 · Synced Oct 19, 2026, 4:17 PM EDT
Completed Phase 4 Interventional

Comparison FloShield Air System Versus Clearify Visualization System (D-HELP)

NCT02419911
View directory record Official record
Conditions
Laparoscopic Surgery
Interventions
Laparoscopic surgery, FloShield Defogging and Cleaning System, Clearify Defogging and Cleaning System
Procedure · Device
Lead sponsor
Minimally Invasive Devices, Inc.
Industry
Eligibility
18 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
3
States / cities
South Miami, Florida • Las Vegas, Nevada • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 28, 2015 · Synced Oct 19, 2026, 4:17 PM EDT
Recruiting No phase listed Observational

En-bloc Transurethral Resection of Bladder Tumor (En-bloc TURBT) Specimens Using a Redesigned Surgical Resectoscope Device

NCT04235764
View directory record Official record
Conditions
Bladder Cancer
Interventions
modified resectoscope, TURBT
Device · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 120 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 8, 2026 · Synced Oct 19, 2026, 4:17 PM EDT
Recruiting No phase listed Observational

MRI Guided Management of Occlusive Peripheral Arterial Disease

NCT06782100
View directory record Official record
Conditions
Peripheral Vascular Diseases
Interventions
Not listed
Lead sponsor
The Methodist Hospital Research Institute
Other
Eligibility
18 Years and older
Enrollment
175 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 19, 2026 · Synced Oct 19, 2026, 4:17 PM EDT
Completed Phase 1 Interventional Results available

Study to Evaluate Effects of Vorinostat and HXTC on Persistent HIV-1 Infection in HIV-Infected Subjects Started on Antiretroviral Therapy (ART)

NCT03212989
View directory record Official record
Conditions
HIV-1 Infection
Interventions
Vorinostat, HXTC
Drug · Biological
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 64 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated May 12, 2023 · Synced Oct 19, 2026, 4:17 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Health Outcomes After Participating in Exercise (HOPE)

NCT03430115
View directory record Official record
Conditions
Weight Loss, Obesity, Aging
Interventions
Not listed
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
60 Years and older
Enrollment
588 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2021
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 15, 2021 · Synced Oct 19, 2026, 4:17 PM EDT
Recruiting Phase 1Phase 2 Interventional

Clinical Study of SNK01 in Participants With Moderate Alzheimer's Disease

NCT06189963
View directory record Official record
Conditions
Moderate Alzheimer Disease
Interventions
SNK01, Placebo
Biological · Other
Lead sponsor
NKGen Biotech, Inc.
Industry
Eligibility
40 Years to 85 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
7
States / cities
Glendale, California • Santa Ana, California • Tarzana, California + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 2, 2026 · Synced Oct 19, 2026, 4:17 PM EDT
Completed Phase 2Phase 3 Interventional

Risk Reduction for Alzheimer's Disease

NCT02913664
View directory record Official record
Conditions
Cognitively Normal Older Adults, Hypertension, Subjective Cognitive Decline, Family History of Alzheimer's Disease
Interventions
Angiotensin II receptor blocker (ARB, losartan) and calcium channel blocker (CCB, amlodipine), Aerobic Exercise Training, Usual Care, Stretching Exercise
Drug · Behavioral · Other
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
60 Years to 85 Years
Enrollment
513 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
4
States / cities
Kansas City, Kansas • Baton Rouge, Louisiana • St Louis, Missouri + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 15, 2022 · Synced Oct 19, 2026, 4:17 PM EDT
Enrolling by invitation Phase 1Phase 2 Interventional

A Study of the Safety and Efficacy of Prime Editing (PM359) in Participants With p47phox Autosomal Recessive Chronic Granulomatous Disease (CGD )

NCT06559176
View directory record Official record
Conditions
Chronic Granulomatous Disease, Granulomatous Disease, Chronic
Interventions
PM359
Biological
Lead sponsor
Prime Medicine, Inc.
Industry
Eligibility
6 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
3
States / cities
Los Angeles, California • Bethesda, Maryland • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 6, 2026 · Synced Oct 19, 2026, 4:17 PM EDT
Not listed No phase listed Observational

The PIONEER Initiative: Precision Insights On N-of-1 Ex Vivo Effectiveness Research Based on Individual Tumor Ownership (Precision Oncology)

NCT03896958
View directory record Official record
Conditions
Cancer, All Types, Cancer of Liver, Cancer of Stomach, Cancer of Head and Neck, Cancer of Rectum, Cancer of Kidney, Cancer of Esophagus, Cancer of Colon, Cancer Skin, Cancer of Cervix, Cancer, Metastatic, Cancer of Larynx, Cancer of Neck, Cancer of Lung, Cancer of Brain and Nervous System, Cancer of Vulva, Disseminated, Cancer of Pancreas, Sarcoma, GIST, Small-cell Lung Cancer, Adenocarcinoma Lung, Cancer of Prostate, Cancer, Advanced, Adrenal Cancer, Testicular Cancer, Uterine Cancer, Bronchoalveolar Cell Lung Cancer, Cancer Unknown Primary, Glioblastoma Multiforme, Oligodendroglioma, Breast Cancer, Renal Cell Carcinoma, Hepatocellular Carcinoma, Cholangiocarcinoma, Squamous Cell Carcinoma, Transitional Cell Carcinoma, Cancer, Other, Cancer, Anal, Melanoma, Cancer, Bile Duct, Cancer, Bladder, Cancer Cords Vocal, Cancers Cell Neuroendocrine, Cancer Differentiated Poorly, Cancer, Anaplastic Thyroid
Interventions
Not listed
Lead sponsor
SpeciCare
Industry
Eligibility
1 Month to 99 Years
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
Gainesville, Georgia
Source: ClinicalTrials.gov public record
Updated Dec 4, 2020 · Synced Oct 19, 2026, 4:17 PM EDT
Recruiting Phase 1Phase 2 Interventional

A Study to Investigate the Efficacy and Safety of an Infusion of IOV-4001 in Adult Participants With Unresectable or Metastatic Melanoma or Stage III or IV Non-small-cell Lung Cancer

NCT05361174
View directory record Official record
Conditions
Unresectable Melanoma, Metastatic Melanoma, Stage III Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer
Interventions
IOV-4001
Biological
Lead sponsor
Iovance Biotherapeutics, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2029
U.S. locations
11
States / cities
Los Angeles, California • Miami, Florida • Orlando, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Jun 11, 2026 · Synced Oct 19, 2026, 4:17 PM EDT
Completed Phase 2 Interventional

Celecoxib in Preventing Lung Cancer in Former Heavy Smokers

NCT00055978
View directory record Official record
Conditions
Lung Cancer
Interventions
celecoxib, placebo
Drug · Other
Lead sponsor
University of California, Los Angeles
Other
Eligibility
45 Years and older
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2009
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jun 20, 2011 · Synced Oct 19, 2026, 4:17 PM EDT
Completed Phase 3 Interventional Results available

Study to Assess the Efficacy and Safety of Beclomethasone Dipropionate in Adolescent and Adult Patients 12 Years of Age and Older With Persistent Asthma

NCT02513160
View directory record Official record
Conditions
Persistent Asthma
Interventions
Beclomethasone Dipropionate 640, Placebo, Beclomethasone dipropionate via 320 mcg BAI, albuterol/salbutamol, Beclomethasone dipropionate via 320 mcg MDI
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
12 Years and older
Enrollment
713 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
75
States / cities
Peoria, Arizona • Downey, California • Huntington Beach, California + 59 more
Source: ClinicalTrials.gov public record
Updated Nov 9, 2021 · Synced Oct 19, 2026, 4:17 PM EDT
Enrolling by invitation Phase 1 Interventional

Rollover Study From EXG-US-01

NCT05868499
View directory record Official record
Conditions
Telomere Biology Disorders With Bone Marrow Failure
Interventions
EXG34217
Biological
Lead sponsor
Elixirgen Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 12, 2024 · Synced Oct 19, 2026, 4:17 PM EDT
Terminated Phase 1Phase 2 Interventional

Safety, Tolerability, and Anti-Tumor Activity of AFM24 in Combination With SNK01 in Subjects With Advanced/Metastatic EGFR-Expressing Cancers

NCT05099549
View directory record Official record
Conditions
Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Colorectal Neoplasms, Advanced Solid Tumor, Refractory Tumor, Metastatic Tumor
Interventions
AFM24, SNK01
Drug · Biological
Lead sponsor
NKGen Biotech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
3
States / cities
Los Angeles, California • Santa Monica, California • Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 1, 2024 · Synced Oct 19, 2026, 4:17 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Open Label, Study Of Efficacy and Safety Of AVR-RD-01 for Treatment-Naive Subjects With Classic Fabry Disease

NCT03454893
View directory record Official record
Conditions
Fabry Disease
Interventions
AVR-RD-01
Drug
Lead sponsor
AVROBIO
Industry
Eligibility
16 Years to 50 Years · Male only
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
2
States / cities
Hackensack, New Jersey • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 5, 2024 · Synced Oct 19, 2026, 4:17 PM EDT
Completed Not applicable Interventional

Blood Flow Restriction Exercise Study

NCT02868021
View directory record Official record
Conditions
Osteoarthritis, Knee
Interventions
Strength testing, Short Physical Performance Battery (SPPB), Six-minute walk (SMW), Numerical pain scale, Self-assessed function, Muscle biopsies, Determination of 1 Repetition Maximum (1-RM), Blood flow restriction exercise, Borg CR10 scale
Device · Behavioral · Procedure
Lead sponsor
University of Florida
Other
Eligibility
55 Years to 80 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Jul 24, 2019 · Synced Oct 19, 2026, 4:17 PM EDT
Active, not recruiting Not applicable Interventional

3 Tesla MRI in Patients With Bladder Cancer

NCT00938145
View directory record Official record
Conditions
Bladder Cancer
Interventions
Specimen Ultra-High field MRI, chemotherapy, Cystectomy and Lymphadenectomy
Procedure · Drug
Lead sponsor
University of Cincinnati
Other
Eligibility
18 Years and older
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2026
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 11, 2025 · Synced Oct 19, 2026, 4:17 PM EDT
Completed Phase 1Phase 2 Interventional

A Relapse Prevention Program for Reducing Relapse and Fear of Food in People With Anorexia Nervosa

NCT00627341
View directory record Official record
Conditions
Eating Disorders
Interventions
Food Exposure Therapy and Ritual Prevention with Motivational Enhancement for Relapse Prevention in Anorexia Nervosa (AN-EX/RP), Cognitive behavioral therapy (CBT)
Behavioral
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
16 Years to 45 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 11, 2012 · Synced Oct 19, 2026, 4:17 PM EDT
Completed Phase 1 Interventional

Phase I Study of Triciribine Phosphate Monohydrate (TCN-PM, VD-0002) in Adult Subjects With Metastatic Cancer

NCT00363454
View directory record Official record
Conditions
Cancer
Interventions
Triciribine Phosphate Monohydrate
Drug
Lead sponsor
Prescient Therapeutics, Ltd.
Industry
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Aug 9, 2016 · Synced Oct 19, 2026, 4:17 PM EDT
Recruiting Phase 2 Interventional

ExCrossV Multi Site Trial for Vascularized High Risk Keratoplasty

NCT06753916
View directory record Official record
Conditions
Corneal Transplant Failure
Interventions
Corneal Donor Tissue with Cross Linking, Corneal Donor Tissue without Cross Linking
Procedure
Lead sponsor
Massachusetts Eye and Ear Infirmary
Other
Eligibility
18 Years and older
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
12
States / cities
Irvine, California • Los Angeles, California • San Francisco, California + 9 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Oct 19, 2026, 4:17 PM EDT
Completed No phase listed Observational

Longterm Follow-up of Subjects Treated With bb2121

NCT02786511
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Safety and efficacy assessments
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
9
States / cities
Palo Alto, California • Bethesda, Maryland • Boston, Massachusetts + 4 more
Source: ClinicalTrials.gov public record
Updated Jan 22, 2020 · Synced Oct 19, 2026, 4:17 PM EDT
Active, not recruiting Phase 1 Interventional

Giving Chemotherapy for a Shortened Amount of Time Before a Stem Cell Transplantation

NCT04098393
View directory record Official record
Conditions
Hematologic Malignancies
Interventions
Busulfan 3.2 mg/kg/day, Fludarabine, Melphalan, Antithymocyte globulin (ATG), Busulfan 0.8 mg/kg, Allogeneic hematopoietic cell transplantation (Allo-HCT)
Drug · Procedure
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Oct 19, 2026, 4:17 PM EDT